Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court

After back-to-back setbacks in its high-stakes Gilenya patent defense, Novartis is taking its arguments all the way to the Supreme Court.

Wednesday, Novartis said it plans to petition the Supreme Court to take up the case after the U.S. Court of Appeals for the Federal Circuit rejected its bid to rehear the case.